Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized Controlled, Open-label, Multicenter Clinical Trial of the Efficacy and Safety of Aflibercept Intravitreal Injection (Zhuochuming®) With a 3-month Loading Phase Followed by Treat-and-extend Regimen in Treatment-naïve Patients With Diabetic Macular Edema

NCT07612904 is registered in ClinicalTrials.gov with The Third Peoples Hospital of Dalian as lead sponsor.

NCT NCT07612904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized Controlled, Open-label, Multicenter Clinical Trial of the Efficacy and Safety of Aflibercept Intravitreal Injection (Zhuochuming®) With a 3-month Loading Phase Followed by Treat-and-extend Regimen in Treatment-naïve Patients With Diabetic Macular Edema
Lead sponsor
The Third Peoples Hospital of Dalian
Phase
Phase 4
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
July 31, 2028
Enrollment
186 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema (dme)